about
Pharmaceutical-grade albumin: impaired drug-binding capacity in vitroDifferences in the serum binding determinants of isradipine and darodipine--consequences for serum protein binding in various diseasesTianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failureDisopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phasesPlasma protein binding of azapropazone in patients with kidney and liver diseasePharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction.Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.Disease states and drug pharmacokinetics.Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients.Plasma and tissue binding considerations in drug disposition.Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses.The effect of renal transplantation on plasma protein binding.Drug-binding properties of rat alpha 1-foetoprotein. Binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxin and cholic acid.The clinical relevance of plasma protein binding changes.The effects of pH, temperature and protein concentration on the in vitro binding of flutamide to human serum albumin.Serum albumin level interferes with the effect of donepezil in Alzheimer's disease.Postoperative course of plasma protein binding of lignocaine, ropivacaine and bupivacaine in sheep.
P2860
Q24798284-0E5262C2-BCC4-4BD1-8E84-E5F4716C011BQ34398001-40041B02-400A-48B9-8245-143ED345B801Q34398093-EBA2DDF9-A785-4AC7-8394-1A42C5290BC3Q34420976-877AC33D-4F50-46E4-AE3C-47CA4FFF640DQ34448774-85618D58-2682-4693-AB92-F80C85DC38AEQ36897388-AB1F0E44-28E3-48FE-8554-72A00B1A8822Q37441778-8F69A28B-2906-4668-99C2-AB81136F1B01Q37818164-6EEC4CF5-447D-4D30-A721-999A5040312AQ38689435-A8080207-F5CF-448B-9139-B9E1410356F9Q39542480-2BFCC839-8837-4098-912A-747919C98793Q40153516-E4A062B2-12E5-4CA8-805E-B55B9BD88894Q40669692-5EF6C4CA-1123-4925-8FE8-82F5DDDB6D4EQ41134213-B552DD56-8CA6-4F5E-855E-8598BFD4C1F0Q42847733-82D95E92-85A3-429B-AC8E-7D8A4D095173Q43830944-5574D245-2254-46E1-9178-9C0597567577Q44969774-D28690FE-2B18-454D-AA4E-F42C37A7FA56Q46140524-A77E631A-8539-4D4A-A4EF-96ABCEE40DD2Q51694174-ECAFEE24-AFC0-4460-9E72-8731285D70BA
P2860
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年学术文章
@wuu
1978年学术文章
@zh-cn
1978年学术文章
@zh-hans
1978年学术文章
@zh-my
1978年学术文章
@zh-sg
1978年學術文章
@yue
1978年學術文章
@zh
1978年學術文章
@zh-hant
name
Diseases and drug protein binding.
@en
type
label
Diseases and drug protein binding.
@en
prefLabel
Diseases and drug protein binding.
@en
P2093
P1476
Diseases and drug protein binding.
@en
P2093
Giudicelli JF
Tillement JP
P304
P356
10.2165/00003088-197803020-00004
P577
1978-03-01T00:00:00Z
P6179
1025293471